In February 2020, the FDA recalled Belviq (lorcaserin) and Belviq XR after a study associated long term use with certain cancers. The manufacturer of the drug, Eisai Inc., withdrew the drug from the market.
The FDA approved Lorcaserin in 2012. Shortly after Belviq was approved, the FDA authorized a clinical study to analyze cardiovascular issues with the drug, however the study found that patients who took Belviq were at a higher risk for certain cancers including:
- Colorectal cancer
If you or someone you know has taken Belviq for at least a year since 2012 and developed lung, pancreatic and colorectal cancer, contact us for a free consultation at 1-888-632-3495.